Clinical Trial Update: Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of the anti-CTLA-4 monoclonal antibody CP-675,206 for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• CP-675,206

Snippet

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra | Conditions: Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection | Phase 2 | Status: COMPLETED